Cinclus Pharma Holding AB (publ)
Cinclus Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops small molecules for the treatment of gastric acid-related diseases in China. The company's lead product is linaprazan glurate, a potassium-competitive acid blocker that has completed Phase II clinical trial to treat gastroesophageal reflux disease. It also develops linaprazan glurate with antibiotics, which is in … Read more
Cinclus Pharma Holding AB (publ) (J8P) - Net Assets
Latest net assets as of September 2025: €429.91 Million EUR
Based on the latest financial reports, Cinclus Pharma Holding AB (publ) (J8P) has net assets worth €429.91 Million EUR as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€587.90 Million) and total liabilities (€157.99 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €429.91 Million |
| % of Total Assets | 73.13% |
| Annual Growth Rate | 63.46% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 80.18 |
Cinclus Pharma Holding AB (publ) - Net Assets Trend (2021–2024)
This chart illustrates how Cinclus Pharma Holding AB (publ)'s net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Cinclus Pharma Holding AB (publ) (2021–2024)
The table below shows the annual net assets of Cinclus Pharma Holding AB (publ) from 2021 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | €555.33 Million | +823.09% |
| 2023-12-31 | €-76.80 Million | -160.53% |
| 2022-12-31 | €126.87 Million | -0.18% |
| 2021-12-31 | €127.10 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Cinclus Pharma Holding AB (publ)'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 62691300000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | €1.33 Billion | 239.02% |
| Total Equity | €555.33 Million | 100.00% |
Cinclus Pharma Holding AB (publ) Competitors by Market Cap
The table below lists competitors of Cinclus Pharma Holding AB (publ) ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Hwa Sung Ind
KO:002460
|
$48.66 Million |
|
ASG Corp
VN:ASG
|
$48.67 Million |
|
Ilshinstone
KO:007110
|
$48.68 Million |
|
Thor Medical ASA
OL:TRMED
|
$48.68 Million |
|
Lam Dong Mineral and Building Material JSC
VN:LBM
|
$48.65 Million |
|
AGTech Holdings Limited
PINK:AGTEF
|
$48.64 Million |
|
MAYO Human Capital Inc.
TWO:6738
|
$48.62 Million |
|
Gevelot
PA:ALGEV
|
$48.61 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Cinclus Pharma Holding AB (publ)'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from -76,800,000 to 555,330,000, a change of 632,130,000.
- Net loss of 168,031,000 reduced equity.
- New share issuances of 715,000,000 increased equity.
- Other factors increased equity by 85,161,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €-168.03 Million | -30.26% |
| Share Issuances | €715.00 Million | +128.75% |
| Other Changes | €85.16 Million | +15.34% |
| Total Change | €- | % |
Book Value vs Market Value Analysis
This analysis compares Cinclus Pharma Holding AB (publ)'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.13x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has decreased from 0.57x to 0.13x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2021-12-31 | €2.73 | €1.55 | x |
| 2022-12-31 | €2.73 | €1.55 | x |
| 2023-12-31 | €-1.65 | €1.55 | x |
| 2024-12-31 | €11.93 | €1.55 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Cinclus Pharma Holding AB (publ) utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -30.26%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -3668.80%
- • Asset Turnover: 0.01x
- • Equity Multiplier: 1.08x
- Recent ROE (-30.26%) is above the historical average (-71.64%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2021 | -60.00% | 0.00% | 0.00x | 1.16x | €-88.98 Million |
| 2022 | -196.32% | -2356.20% | 0.06x | 1.46x | €-261.76 Million |
| 2023 | 0.00% | -3609.97% | 0.06x | 0.00x | €-207.44 Million |
| 2024 | -30.26% | -3668.80% | 0.01x | 1.08x | €-223.56 Million |
Industry Comparison
This section compares Cinclus Pharma Holding AB (publ)'s net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $9,244,379,027
- Average return on equity (ROE) among peers: -92.52%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Cinclus Pharma Holding AB (publ) (J8P) | €429.91 Million | -60.00% | 0.37x | $48.65 Million |
| 26U (26U) | $6.75 Million | -514.32% | 1.08x | $248.33K |
| 27N0 (27N0) | $11.56 Million | -0.93% | 0.00x | $4.66K |
| China Resources Pharmaceutical Group Limited (640) | $90.18 Billion | 4.60% | 1.68x | $940.63 Million |
| CIG WIRELESS (6CW) | $27.09 Million | -110.19% | 3.19x | $56.65 Million |
| Solasia Pharma K.K (9SO) | $1.16 Billion | -167.91% | 0.18x | $34.42 Million |
| Apontis Pharma AG (APPH) | $3.46 Million | -34.21% | 7.59x | $11.70 Million |
| Akebia Therapeutics Inc (AX9) | $635.93 Million | -22.58% | 0.57x | $283.56 Million |
| Biofrontera AG (B8FK) | $-12.89 Million | 0.00% | 0.00x | $3.86 Million |
| AVALA RES (CVJ) | $91.87 Million | -27.32% | 0.11x | $113.22K |
| Deciphera Pharmaceuticals Inc (D05) | $341.69 Million | -52.37% | 0.33x | $2.11 Billion |